A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors

Conclusion The safety profile of BV in patients with solid tumors was similar to the known safety profile of BV. In solid tumors, BV had modest activity as a single agent, which was similar to other second-line treatments already available to patients.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research